Clinical Trials

  • Principal Investigator:

    Marcus Rebello Pereira, MD
    The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a liver from an HIV-uninfected deceased liver donor (HIVD-). Those participants who have accepted a HIVD- organ will be randomized to be followed in the full study or followed in the nested observational...
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a liver from an HIV-uninfected deceased liver donor (HIVD-). Those participants who have accepted a HIVD- organ will be randomized to be followed in the full study or followed in the nested observational...
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD
    We want to assess the baseline and cumulative seroprevalence of SARS-CoV-2 using serological and molecular assays. We will also administer a survey. Findings from this study will inform; 1) our understanding of changing epidemiology of COVID-19; 2) use of serological assays and testing algorithms, and 3) approaches to managing psychosocial stress in the community.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD
    Pfizer and Columbia University Irving Medical Center are conducting a trial to learn about the safety and effectiveness of an experimental COVID-19 treatment, nirmatrelvir co-packaged with ritonavir, for children with COVID-19 that are at risk of the infection getting worse. Nirmatrelvir/ritonavir has been shown to be effective in fighting SARS-CoV-2 (the virus that causes COVID-19) in laboratory experiments and has been previously evaluated for safety in Phase 1 trials with healthy participants. The US FDA has granted Emergency Use Authorization (EUA) to nirmatrelvir/ritonavir for the...
  • Principal Investigator:

    Michael T Yin, MD
    We are seeking volunteers who have been diagnosed with COVID-19 by a healthcare provider or by lab testing. We are also looking for volunteers who have never tested positive for COVID-19 and have not received a COVID-19 vaccine. The study, also known as C-PIC, will be looking at antibody levels and how long the virus remains in the body. We are also studying the long-term complications that can occur after recovery from an acute COVID-19 infection, commonly referred to as long-COVID, long-haul COVID, and post-acute sequelae of SARS-CoV-2 (PASC). At each visit, you will be asked to complete a...
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    The purpose of this study is to evaluate the safety, immune response, and efficacy of the Moderna mRNA-1273 SARS-CoV-2 vaccine in solid organ transplant recipients and healthy controls. Adult kidney and liver transplant recipients and healthy control participants who are at least 18 years of age will be enrolled. The current study aims to evaluate the antibody responses following the second dose of mRNA-1273 vaccine among adult recipients of kidney or liver transplants, and is expected to provide initial clinical information whether this population of immunocompromised participants, has...
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD
    We are looking for HIV-negative individuals 18 to 60 years old who are interested in learning more about HIV prevention research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1.5-hour education visit to learn about the research we do. The education visit will help you decide if you want to participate in one of our studies. You will be compensated for the visit. Your responses to this questionnaire will be kept strictly confidential.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD
    We are looking for HIV-negative individuals 18 to 60 years old who are interested in learning more about HIV prevention research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1-hour education visit to learn about the research we do. The education visit will help you decide if you want to participate in one of our studies. You will be compensated for the visit. Your responses to this questionnaire will be kept strictly confidential.
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    In this research study, we want to find out how well patients that receive a kidney from an HIV-positive (HIV+) donor do over 10 years compared to patients who receive a kidney from an HIV-negative (HIV-) donor. This research study is for adults who are HIV+ and are being evaluated for or are waitlisted to receive a kidney transplant. It is also available for adults who are HIV+ and previously received a kidney-only transplant under a HOPE Act protocol. To take part in this study you must be willing to accept a kidney from an HIV+ or HIV- donor. If you decide not to join this study, you will...
  • Principal Investigator:

    Michael T Yin, MD
    We are doing a research study to find out if Long-Acting Injectable anti-HIV medications will be more successful than standard pills for people who have a hard time taking their HIV pills. If you are over the age of 18 years old, have been prescribed HIV medications but have had difficulty getting undetectable viral load (when the levels of virus in the bloodstream are so low that they can't be measured), you may be eligible. You may receive up to $1100 for the first 5 months of participation. Contact us to find out more about this study.

Pages